STOCKSCREENR

SLXN

NASDAQ

Silexion Therapeutics Ltd.

$0.60-0.01(-2.25%)Mkt Cap: $335.63K

Key Stats

Market Cap

$335.63K

P/E Ratio

-0.07

EPS

$-8.96

Dividend Yield

0.00%

52-Week Range

$0.47 — $22.36

Volume

166.21K

Avg Volume

59.83K

Beta

0.06

Price Alerts for SLXN

Get alerted when SLXN hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

-0.07

Forward P/E

—

PEG Ratio

0.02

P/S (TTM)

0.00

P/B (TTM)

1.29

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-3.88%

ROA (TTM)

-1.65%

ROIC

—

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

—

Debt/Equity

0.18

Current Ratio

2.41

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-41.83%

EPS Growth (5Y)

-25.67%

Sales Growth (3Y)

+0.00%

Sales Growth (5Y)

+0.00%

EPS Est (This Year)

$-4.39

EPS Est (Next Year)

$-4.37

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$1.92

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

560.96K

Float

560.96K

Free Float %

100.00%

About

Sector

Healthcare

Industry

Biotechnology

Country

IL

Exchange

NASDAQ

IPO Date

2024-08-16

Employees

11

CEO

Ilan Hadar

Index Membership

—

Website

https://silexion.com

Silexion Therapeutics Ltd. (SLXN) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $335.63K, a P/E ratio of -0.07, SLXN is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare SLXN against other stocks using dozens of fundamental and technical filters.

Similar Stocks

IBO.V

Universal Ibogaine Inc.

$0.01

-50.00%

$1.56M

CARM

Carisma Therapeutics, Inc.

$0.04

+0.53%

$1.58M

CLDI

Calidi Biotherapeutics, Inc.

$0.22

-8.69%

$1.59M

WINT

Windtree Therapeutics, Inc.

$0.01

-10.00%

$455.07K

CMND

Clearmind Medicine Inc.

$0.94

+15.62%

$128.57K

CYTO

Altamira Therapeutics Ltd.

$0.30

+100.00%

$1.13M

Frequently Asked Questions

What is Silexion Therapeutics Ltd.'s P/E ratio?

Silexion Therapeutics Ltd. (SLXN) has a trailing twelve-month (TTM) P/E ratio of -0.07. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Silexion Therapeutics Ltd. pay a dividend?

No, Silexion Therapeutics Ltd. (SLXN) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Silexion Therapeutics Ltd.'s market cap?

Silexion Therapeutics Ltd. (SLXN) has a market capitalization of $335,625, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.